Safety, Tolerability, and Efficacy of Raltegravir in a Diverse Cohort of HIV-Infected Patients: 48-Week Results from the REALMRK Study-Reference-Cited by-同舟云学术

Safety, Tolerability, and Efficacy of Raltegravir in a Diverse Cohort of HIV-Infected Patients: 48-Week Results from the REALMRK Study

Published:2013-06 Issue:6 Volume:29 Page:859-870
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Squires Kathleen E.¹,Bekker Linda-Gail²,Eron Joseph J.³,Cheng Benjamin⁴,Rockstroh Juergen K.⁵,Marquez Farid⁶,Kumar Princy⁷,Thompson Melanie⁸,Campo Rafael E.⁹,Mounzer Karam¹⁰,Strohmaier Kim M.¹¹,Lu Chengxing¹¹,Rodgers Anthony¹¹,Jackson Beth E.¹¹,Wenning Larissa A.¹¹,Robertson Michael¹¹,Nguyen Bach-Yen T.¹¹,Sklar, for the REALMRK Investigator Peter¹¹

Affiliation:

1. Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania.

2. University of Capetown, Capetown, South Africa.

3. University of North Carolina, Chapel Hill, North Carolina.

4. International HIV Partners, Lake Forest Park, Washington.

5. University of Bonn, Bonn-Venusburg, Germany.

6. Palm Springs Research Institute, Hialeah, Florida.

7. Georgetown University, Washington, D.C.

8. AIDS Research Consortium, Atlanta, Georgia.

9. University of Miami, Miami, Florida.

10. Philadelphia FIGHT, Philadelphia, Pennsylvania.

11. Merck Sharp & Dohme Corp., Whitehouse Station, New Jersey.